Sophie Fredslund Madsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sophie Fredslund Madsen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Gunnar Hilmar Gislason
Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte , Hospitalsvej 1, 2900 Hellerup
2 shared publications - Jarl Emanuel Strange
Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen
2 shared publications - Morten Lamberts
Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark
2 shared publications - Thomas Kümler
Department of Cardiology, Herlev University Hospital, Herlev, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Clinical Translational Research Steno Diabetes Center Copenhagen, Herlev, Denmark
2 shared publications - Caroline Sindet-Pedersen
Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark
1 shared publication Caroline Sindet‐Pedersen
Danish Heart Foundation Copenhagen Denmark
1 shared publication
Latest Publications
- Open Access
- 5 December 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (23) , e030191
Short‐ and Long‐Term Mortality for Patients With and Without a Cancer Diagnosis Following Pulmonary Embolism in Denmark, 2000 to 2020: A Nationwide Study
Background: New treatment regimens have been introduced in the past 20 years, which may influence the short‐ and long‐term prognosis for patients with and without a cancer diagnosis following pulmonary embolism. However, newer studies investigating these trends are lacking. Therefore, we aimed to investigate the 30‐ and 31‐ to 365‐day mortality following pulmonary embolism. Methods and Results: Using the Danish nationwide registries, patients with a diagnosis of pulmonary embolism between 2000 and 2020 were included. Age‐ and sex‐standardized 30‐ and 31‐ to 365‐day mortality was calculated and stratified by cancer status. In total, 60 614 patients (29.6% with recent cancer; mean age, 68.2 years) were included. The 30‐day mortality for patients with no recent cancer decreased from 19.1% (95% CI, 17.9%–20.4%) in 2000 to 7.3% (95% CI, 6.7%–8.0%) in 2018 to 2020 (hazard ratio [HR], 0.36 [95% CI, 0.32–0.40]; P P P P =0.69). Conclusions: From 2000 to 2020, improvements were observed in 30‐day mortality following pulmonary embolism regardless of cancer status. For patients with recent cancer, 31‐ to 365‐day mortality did not improve, whereas a minor improvement was observed for patients without recent cancer.
- 5 December 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (23) , e030191
Open AccessShort‐ and Long‐Term Mortality for Patients With and Without a Cancer Diagnosis Following Pulmonary Embolism in Denmark, 2000 to 2020: A Nationwide Study
Background: New treatment regimens have been introduced in the past 20 years, which may influence the short‐ and long‐term prognosis for patients with and without a cancer diagnosis following pulmonary embolism. However, newer studies investigating these trends are lacking. Therefore, we aimed to investigate the 30‐ and 31‐ to 365‐day mortality following pulmonary embolism. Methods and Results: Using the Danish nationwide registries, patients with a diagnosis of pulmonary embolism between 2000 and 2020 were included. Age‐ and sex‐standardized 30‐ and 31‐ to 365‐day mortality was calculated and stratified by cancer status. In total, 60 614 patients (29.6% with recent cancer; mean age, 68.2 years) were included. The 30‐day mortality for patients with no recent cancer decreased from 19.1% (95% CI, 17.9%–20.4%) in 2000 to 7.3% (95% CI, 6.7%–8.0%) in 2018 to 2020 (hazard ratio [HR], 0.36 [95% CI, 0.32–0.40]; P P P P =0.69). Conclusions: From 2000 to 2020, improvements were observed in 30‐day mortality following pulmonary embolism regardless of cancer status. For patients with recent cancer, 31‐ to 365‐day mortality did not improve, whereas a minor improvement was observed for patients without recent cancer.
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Increased risk of long-term mortality following pulmonary embolism in Denmark, 2000–2020: a nationwide trend study
Background: New diagnostics and treatment regimens have been introduced in the last 20 years which may have influenced the prognosis of pulmonary embolism (PE). However, there is a lack of studies investigating temporal trend in short- and long-term mortality following PE in different subgroups. Purpose: We aimed to investigate temporal trends in short- and long-term mortality following PE according to age, sex, and cancer status. Method: This study was based on data from Danish national registries. All patients with a first-time inpatient hospital diagnosis of PE between the 1st of January 2000 through 3rd of December 2020 were included in the study. Mortality was calculated as the proportion of patients who died within 30 days and 31–365 days, respectively, and were presented with 95% confidence intervals (CI), and additionally stratified into categories of age groups (18–39, 40–59, 60–79, and 80–100 years), sex (male/female) and cancer status (no cancer/cancer). Cancer was defined as a cancer diagnosis registered within 6 months prior to the PE diagnosis. Results: In total 62,750 patients had a first-time PE during the study period. The mean age of the study population was 68.3 years (sd), and 32,617 (51.9%) were women and 18,719 (29.83%) of patients had cancer. The 30-day mortality for age groups, sex, and cancer status decreased during the study period 2000–2020 (Figure 1A). The 31–365-day mortality for age group 40–59 years increased from 5.7% [95% CI: 3.7–8.5] in 2000 to 9.5% [95% CI: 7.5–11.9] in 2019. Age group 80–100 years increased from 18.5% [95% CI: 14.8–22.8] in 2000 to 23.5% [95% CI: 21.0–26.2] in 2019. No temporal differences were observed for age groups 18–39 and 60–79 years. Mortality for cancer-associated PE increased from 24.8% [95% CI: 19.8–30.6] in 2000 to 29.9% [95% CI: 27.4–32.4] in 2019 (Figure 1B). Conclusion: Despite overall mortality following PE has improved, our data suggest that short-term mortality following pulmonary embolism has improved considerably while long-term mortality were increased. Future studies should assess whether this phenomenon is due to a different patient risk profile (e.g. cancer) or lack of longer term care (e.g. rehabilitation program, withdrawal of antithrombotic treatment). Funding Acknowledgement: Type of funding sources: None.
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessIncreased risk of long-term mortality following pulmonary embolism in Denmark, 2000–2020: a nationwide trend study
Background: New diagnostics and treatment regimens have been introduced in the last 20 years which may have influenced the prognosis of pulmonary embolism (PE). However, there is a lack of studies investigating temporal trend in short- and long-term mortality following PE in different subgroups. Purpose: We aimed to investigate temporal trends in short- and long-term mortality following PE according to age, sex, and cancer status. Method: This study was based on data from Danish national registries. All patients with a first-time inpatient hospital diagnosis of PE between the 1st of January 2000 through 3rd of December 2020 were included in the study. Mortality was calculated as the proportion of patients who died within 30 days and 31–365 days, respectively, and were presented with 95% confidence intervals (CI), and additionally stratified into categories of age groups (18–39, 40–59, 60–79, and 80–100 years), sex (male/female) and cancer status (no cancer/cancer). Cancer was defined as a cancer diagnosis registered within 6 months prior to the PE diagnosis. Results: In total 62,750 patients had a first-time PE during the study period. The mean age of the study population was 68.3 years (sd), and 32,617 (51.9%) were women and 18,719 (29.83%) of patients had cancer. The 30-day mortality for age groups, sex, and cancer status decreased during the study period 2000–2020 (Figure 1A). The 31–365-day mortality for age group 40–59 years increased from 5.7% [95% CI: 3.7–8.5] in 2000 to 9.5% [95% CI: 7.5–11.9] in 2019. Age group 80–100 years increased from 18.5% [95% CI: 14.8–22.8] in 2000 to 23.5% [95% CI: 21.0–26.2] in 2019. No temporal differences were observed for age groups 18–39 and 60–79 years. Mortality for cancer-associated PE increased from 24.8% [95% CI: 19.8–30.6] in 2000 to 29.9% [95% CI: 27.4–32.4] in 2019 (Figure 1B). Conclusion: Despite overall mortality following PE has improved, our data suggest that short-term mortality following pulmonary embolism has improved considerably while long-term mortality were increased. Future studies should assess whether this phenomenon is due to a different patient risk profile (e.g. cancer) or lack of longer term care (e.g. rehabilitation program, withdrawal of antithrombotic treatment). Funding Acknowledgement: Type of funding sources: None.